

This material is an English translation of the press release announced on January 10, 2020. In Japanese, and the Japanese release is given priority about the content and the interpretation.

January 10, 2020

Announcement of Establishment of New Company in Malaysia

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as Hisamitsu) announces that Hisamitsu has resolved to establish new company in Malaysia, Hisamitsu Pharmaceutical Malaysia Sdn. Bhd. at the board of director's meeting held on January 10, 2020.

1. Purpose of establishment

To ensure future growth of Hisamitsu group, Hisamitsu decided to establish new company with following overview in important market, Malaysia, for the purpose of strengthening sales of Hisamitsu products in Malaysia.

2. Overview of new company

Name of the company: Hisamitsu Pharmaceutical Malaysia Sdn. Bhd.

Location: Kuala Lumpur City in Malaysia

Representative Director: Kyu Saito (Director & Executive Officer, Head of International Division, Hisamitsu Pharmaceutical Co., Inc.)

Contents of business: Sales and Marketing of pharmaceutical

Capital: 10,000,000 MYR

Shareholding ratio: Hisamitsu Pharmaceutical Co., Inc. 100%

Date of Establishment: October, 2020 (tentative)

The impact on Hisamitsu's financial performance by establishing the new company for fiscal year ending February 29, 2020 is to be negligible. Therefore no change is made on forecast of this fiscal year. Updates on details of the new company or the forecast will be announced promptly, if any changes were made.